Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Industry Challenges Contribute to Financial Toxicity
In this third panel discussion from ONS’s Health Policy Summit in Washington DC, Alan Balch, PhD, Patient Advocate Foundation chief executive officer, Mike Ybarra, MD, FAAEM, FACEP, vice president of medical affairs for the Pharmaceutical Research Manufacturers Association, and Jeannine Walston, a 20-year brain cancer survivor and patient advocate, discuss the challenges of tackling financial toxicity from an industry perspective, how nurses can advocate for patient resources, and much more.
Related Topics
You May Also Like
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Podcast
Michael Pietrack
Hiring Managers Beware: Reverse Rejection Explained!
Article
Jamie Riley
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
Podcast
MSL Talk: Tom Caravela, Josh Corriveau